SG Americas Securities LLC Acquires 53,747 Shares of uniQure N.V. $QURE

SG Americas Securities LLC lifted its holdings in shares of uniQure N.V. (NASDAQ:QURE) by 508.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 64,326 shares of the biotechnology company’s stock after acquiring an additional 53,747 shares during the quarter. SG Americas Securities LLC owned 0.10% of uniQure worth $1,539,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Swiss National Bank bought a new position in uniQure in the 2nd quarter valued at $1,080,000. Sanders Morris Harris LLC bought a new stake in shares of uniQure during the 3rd quarter worth $5,081,000. Vanguard Group Inc. raised its stake in shares of uniQure by 15.7% during the 3rd quarter. Vanguard Group Inc. now owns 1,125,108 shares of the biotechnology company’s stock worth $65,673,000 after purchasing an additional 152,417 shares during the period. Aberdeen Group plc boosted its holdings in shares of uniQure by 6.9% in the 3rd quarter. Aberdeen Group plc now owns 2,939,743 shares of the biotechnology company’s stock worth $171,593,000 after buying an additional 189,029 shares during the last quarter. Finally, Voss Capital LP purchased a new position in shares of uniQure in the 2nd quarter worth about $1,742,000. 78.83% of the stock is currently owned by institutional investors.

uniQure Price Performance

NASDAQ QURE opened at $17.39 on Tuesday. The company has a quick ratio of 10.43, a current ratio of 10.43 and a debt-to-equity ratio of 0.25. The company has a market cap of $1.09 billion, a PE ratio of -5.04 and a beta of 0.75. uniQure N.V. has a 52 week low of $7.76 and a 52 week high of $71.50. The firm’s 50-day simple moving average is $19.11 and its two-hundred day simple moving average is $29.63.

uniQure (NASDAQ:QURE) last posted its earnings results on Tuesday, March 3rd. The biotechnology company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.93) by $0.37. The firm had revenue of $5.57 million during the quarter, compared to the consensus estimate of $4.84 million. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. Research analysts predict that uniQure N.V. will post -3.75 earnings per share for the current year.

Insider Transactions at uniQure

In related news, Director Jack Kaye sold 6,390 shares of the stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $27.28, for a total transaction of $174,319.20. Following the sale, the director owned 20,439 shares of the company’s stock, valued at approximately $557,575.92. This represents a 23.82% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Robert Gut sold 25,613 shares of the firm’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $24.62, for a total value of $630,592.06. Following the completion of the transaction, the director owned 32,342 shares of the company’s stock, valued at approximately $796,260.04. This represents a 44.19% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 81,399 shares of company stock valued at $1,527,645. 4.79% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

QURE has been the subject of a number of research analyst reports. Chardan Capital raised their price objective on shares of uniQure from $16.00 to $31.00 and gave the stock a “buy” rating in a report on Monday, March 9th. Barclays dropped their target price on shares of uniQure from $31.00 to $25.00 and set an “equal weight” rating on the stock in a research note on Monday, March 23rd. Wells Fargo & Company upgraded shares of uniQure from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $15.00 to $60.00 in a research note on Monday, March 9th. Mizuho raised shares of uniQure from a “neutral” rating to an “outperform” rating and lifted their price target for the stock from $12.00 to $35.00 in a report on Wednesday, March 11th. Finally, TD Cowen reiterated a “buy” rating on shares of uniQure in a research note on Tuesday, March 3rd. Ten investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.75.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.